TrialInvestigational new drugs2014

Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.

Kristen K Ciombor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.